Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma reported Q1 2026 results with a net loss of $26.9 million, driven by $22.9 million in R&D expenses as it advances its inhaled pulmonary fibrosis programs. The company highlighted strong liquidity, with $123.1 million in cash on hand plus $316.1 million in net proceeds from its recent $345 million IPO, providing a runway into 2029.
Key figures
- Revenue
- 0
- Guidance
- Cash runway sufficient to fund operations into 2029
- Net loss
- 26869000
- Ipo price
- 18
- Ipo shares
- 19166667
- Ga expenses
- 5020000
- Rd expenses
- 22889000
- Ipo gross proceeds
- 345000000
- Cash and equivalents
- 123127000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.